Diabetes Research Institute
Diabetes is one of the toughest challenges of our time in terms of public health. Ospedale San Raffaele, where diabetes is one of the central themes of research and assistance, in 2007 has gradually institutionalized and consolidated its commitment through the creation of the Diabetes Research Institute (DRI).
The DRI is an international center of excellence for the study, prevention and treatment of diabetes. This goal is pursued through a number of clinical programs in concert with research projects, often extended to the Institute’s internal and external collaborations, especially international.
View all the research and clinical groups here.
Among the many programs that exist within the DRI, some are of particular strategic importance. Examples are: transplantation of pancreatic islets and cell therapies for the induction of immunological tolerance, prevention of type 1 diabetes, modern technologies (eg. insulin pumps and artificial pancreas), study and prevention of diabetes complications and programs of cardio-diabetes and cardio-metabolism in type 2 diabetes. The final outcome of such research is the development of clinical studies to test new hypotheses for the cure of the disease (phase 1 and 2 studies) or improve current therapies (phase 3 studies).
Beta cell biology
Cardiodiabetes and core Lab
Cardiometabolism and clinical trials
Pier Marco Piatti
Complication of diabetes
Regulation of adaptive immunity
Head, Pediatric diabetes Unit
Group leader, Experimental diabetes Unit
Group leader, Regulation of adaptive immunity Unit
Group leader, Cardiodiabetes and core Lab Unit
Group leader, Transplant immunology Unit
Pier Marco Piatti
Clinical group leader, Cardiometabolism and clinical trials Unit
Head, Beta cell biology Unit
Group leader, Complication of diabetes Unit
Two postdoc positions are available in the Regulation of adaptive immunity Unit, headed by Georgia Fousteri